Onconetix, Inc. announced that on February 6, 2024, appointed Thomas Meier, PhD, to the board of directors of the company. Dr. Meier will be a Class I director and will serve for a term expiring at the Company?s 2025 annual meeting of stockholders. Dr. Meier has close to 25 years?

experience as life-science and biotech entrepreneur, executive manager, and Board member. Since June 2022 Dr. Meier has served as Chairman and a member of the Audit and Compensation Committees of Santhera Pharmaceuticals Holding AG. Dr. Meier served on the Board of Santhera since 2017 and stepped down as the company?s CEO in November 2019 after having served 15 years as executive manager of Santhera, the last 8 years as CEO.

In 2020 Dr. Meier became managing partner of Viopas Venture Consulting GmbH, a Swiss consultancy and advisory firm for the healthcare industry. Since 2020, Dr. Meier has served as Board member of Novaremed AG. Dr. Meier has served on the company?s Audit Committee since October 2021 and became Executive Chairman of Novaremed in January 2024.

Since January 2022 Dr. Meier also serves on the Board of Visgenx Inc. (USA). In September 2021 he co-founded SEAL Therapeutics AG, for which he also serves as Chairman. Between July 2020 and November 2021, he served as Chairman of privately held Pharmabiome AG (Switzerland).

Dr. Meier has a PhD in Biology and qualified as lecturer in neurosciences at the Biozentrum, University of Basel (Switzerland). He is an internationally recognized scientist with track record in clinical research of orphan diseases.